The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis

被引:12
作者
Fei, Jeanie Z. [1 ,2 ]
Perruccio, Anthony, V [3 ,4 ,5 ]
Ye, Justine Y. [1 ]
Gladman, Dafna D. [1 ,3 ,6 ,7 ]
Chandran, Vinod [1 ,3 ,6 ,7 ,8 ]
机构
[1] Univ Hlth Network, Ctr Prognosis Studies Rheumat Dis, Krembil Res Inst, Psoriat Arthrit Program, Toronto, ON, Canada
[2] Western Univ, Fac Med, London, ON, Canada
[3] Univ Hlth Network, Krembil Res Inst, Hlth Care & Outcomes Res & Arthrit Program, Toronto, ON, Canada
[4] Univ Toronto, Dalla Lana Sch Publ Hlth, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[5] Univ Toronto, Dept Surg, Toronto, ON, Canada
[6] Univ Toronto, Dept Med, Div Rheumatol, 399 Bathurst St,1E416, Toronto, ON M5T 2S8, Canada
[7] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[8] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
psoriasis; spondyloarthritis; outcome measure; CLINICALLY IMPORTANT IMPROVEMENT; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; RESPONDER INDEXES; REPORTED OUTCOMES; OSTEOARTHRITIS; VALIDATION; PHYSICIANS; BASDAI; JOINT;
D O I
10.1093/rheumatology/kez202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The Psoriatic Arthritis Disease Activity Score (PASDAS) and Disease Activity Index for Psoriatic Arthritis (DAPSA) are composite PsA disease activity measures. We sought to identify the PASDAS and DAPSA cut-off points consistent with patient acceptable symptom state (PASS), the threshold of symptoms beyond which patients consider themselves well, and examine PASS across published PASDAS and DAPSA thresholds for low, moderate and high disease activity. Methods. We used a standard protocol including physician assessment and patient-reported outcomes to prospectively record measures required to calculate PASDAS and DAPSA. We identified PASS thresholds for the PASDAS and DAPSA using receiver operating characteristics curve analyses. We assessed the frequency of reporting acceptable symptom state across disease activity thresholds for PASDAS and DAPSA scores. Results. A total of 229 patients (58.5% male, mean age 55.5 years, mean disease duration 17.1 years) were recruited. The PASS threshold for the PASDAS was 3.79 [area under the curve (AUC) 0.86, sensitivity 0.75, specificity 0.82] and for the DAPSA was 11.10 (AUC 0.91, sensitivity 0.89, specificity 0.82). With the PASDAS, 90% of patients defined as having low disease activity considered their symptom state acceptable, compared with 55% and 17% among those with moderate and high disease activity, respectively. With the DAPSA, 98% of patients in disease remission considered their symptom state acceptable compared with 85, 22 and 18% among those with low, moderate and high disease activity, respectively. Conclusion. We have defined PASS thresholds for PASDAS and DAPSA. The PASDAS target for low disease activity and DAPSA targets of low disease activity or remission align well with PASS.
引用
收藏
页码:69 / 76
页数:8
相关论文
共 50 条
[21]   Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review [J].
Smolen, J. S. ;
Schoels, M. ;
Aletaha, D. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (05) :S48-S50
[22]   Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA) [J].
Leeb, Burkhard F. ;
Haindl, Pia M. ;
Brezinschek, Hans-Peter ;
Mai, Harsono T. H. ;
Deutsch, Christoph ;
Rintelen, Bernhard .
BMC MUSCULOSKELETAL DISORDERS, 2015, 16
[23]   Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care [J].
Salaffi, Fausto ;
Carotti, Marina ;
Gutierrez, Marwin ;
Di Carlo, Marco ;
De Angelis, Rossella .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[24]   Relationship between disease impact scores and C-reactive protein/albumin ratio in patients with psoriatic arthritis [J].
Duran, Tugba Izci ;
Pamukcu, Melih .
CROATIAN MEDICAL JOURNAL, 2022, 63 (02) :141-147
[25]   The Patient Acceptable Symptom State in Female Urinary Incontinence [J].
Sanderson, Derrick J. ;
Zavez, Alexis ;
Meekins, A. Rebecca ;
Eddib, Abeer ;
Lee, Toy G. ;
Barber, Matthew D. ;
Duecy, Erin .
FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2022, 28 (01) :33-39
[26]   The Patient Acceptable Symptom State of Chronic Musculoskeletal Pain Measured on a Visual Analog Scale in Moroccan Patients [J].
Wariaghli, Ghizlane ;
Allali, Fadoua ;
Berrada, Kenza ;
Idrissi, Zineb ;
Hmamouchi, Ihsane ;
Abouqal, Redouane ;
Hajjaj-Hassouni, Najia .
PAIN MEDICINE, 2013, 14 (01) :103-109
[27]   Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis [J].
Arnold, Michael B. ;
Khanna, Dinesh ;
Denton, Christopher P. ;
van Laar, Jacob M. ;
Frech, Tracy M. ;
Anderson, Marina E. ;
Baron, Murray ;
Chung, Lorinda ;
Fierlbeck, Gerhard ;
Lakshminarayanan, Santhanam ;
Allanore, Yannick ;
Riemekasten, Gabriela ;
Steen, Virginia ;
Mueller-Ladner, Ulf ;
Spotswood, Helen ;
Burke, Laura ;
Siegel, Jeffrey ;
Jahreis, Angelika ;
Furst, Daniel E. ;
Pope, Janet E. .
RHEUMATOLOGY, 2018, 57 (01) :152-157
[28]   Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study [J].
Costa, Luisa ;
Caso, Francesco ;
Ramonda, Roberta ;
Del Puente, Antonio ;
Cantarini, Luca ;
Darda, Md Abud ;
Caso, Paolo ;
Lorenzin, Mariagrazia ;
Fiocco, Ugo ;
Punzi, Leonardo ;
Scarpa, Raffaele .
IMMUNOLOGIC RESEARCH, 2015, 61 (1-2) :147-153
[29]   Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy [J].
Chandran, Vinod ;
Maharaj, Ajesh B. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) :573-582
[30]   Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control [J].
Furst, Daniel E. ;
Melody Tran ;
Sullivan, Emma ;
Pike, James ;
Piercy, James ;
Herrera, Vivian ;
Palmer, Jacqueline B. .
CLINICAL RHEUMATOLOGY, 2017, 36 (09) :2045-2054